Clinical Trial Update: Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center [Phase 1]

View source ↗

Summary

A Phase 1 open-label safety study at a single center evaluated omalizumab in combination with oral immunotherapy for food allergies and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Food Allergy

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Stanford University | Conditions: Immune System Diseases | Phase 1 | Status: COMPLETED